|
| 8-hydroxy-7-(p-tolylsulfonyl)-5-(p-tolylsulfonylamino)quinoline |
|
Vibrio |
Stress survival |
Preclinical (in vitro) |
Stanbery L, et al. 2017. Drug Des Devel Ther |
|
Compound 1
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 2
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 3
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
Compound 4
(internal name in literature) |
|
Vibrio |
TCP (Toxin-coregulated pilus) |
Preclinical (in vitro) |
Woodbrey AK, et al. 2018. Biochemistry |
|
| Imidocarb |
|
Escherichia
Yersinia |
TTSS (Type III secretion system)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vitro) |
Pan NJ, et al. 2009. Antimicrob Agents Chemother
|
|
| N-(1,3-dimethyl-2-oxo-6-pyrrolidin-1-yl-2,3-dihydro-1H-benzimidazol-5-yl)-N'-(3,4-dimethylphenyl)urea |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Harmon DE, et al. 2010. Antimicrob Agents Chemother |
|
| 1-{4-[(2-nitrophenyl)sulfonyl]piperazin-1-yl}-2-phenoxyethanone |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-5-chloro-N-(3,4-dichlorophenyl)benzamide |
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Kauppi AM, et al. 2003. Chem Biol |
|
| 2-chloro-4-{5-[(E)-2-(4,6-dihydroxy-5-nitropyrimidin-2-yl)ethenyl]furan-2-yl}benzoic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Eriksson J, et al. 2012. Adv Exp Med Biol |
|
| | | |
